203 related articles for article (PubMed ID: 14747565)
1. Lv2, a novel postentry restriction, is mediated by both capsid and envelope.
Schmitz C; Marchant D; Neil SJ; Aubin K; Reuter S; Dittmar MT; McKnight A
J Virol; 2004 Feb; 78(4):2006-16. PubMed ID: 14747565
[TBL] [Abstract][Full Text] [Related]
2. A novel envelope mediated post entry restriction of murine leukaemia virus in human cells is Ref1/TRIM5α independent.
Oliveira NM; Trikha R; McKnight Á
Retrovirology; 2010 Oct; 7():81. PubMed ID: 20929586
[TBL] [Abstract][Full Text] [Related]
3. Human TRIM5alpha mediated restriction of different HIV-1 subtypes and Lv2 sensitive and insensitive HIV-2 variants.
Kaumanns P; Hagmann I; Dittmar MT
Retrovirology; 2006 Nov; 3():79. PubMed ID: 17087820
[TBL] [Abstract][Full Text] [Related]
4. Role of HIV-2 envelope in Lv2-mediated restriction.
Reuter S; Kaumanns P; Buschhorn SB; Dittmar MT
Virology; 2005 Feb; 332(1):347-58. PubMed ID: 15661166
[TBL] [Abstract][Full Text] [Related]
5. RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction.
Marno KM; O'Sullivan E; Jones CE; Díaz-Delfín J; Pardieu C; Sloan RD; McKnight Á
J Virol; 2017 May; 91(10):. PubMed ID: 28275184
[TBL] [Abstract][Full Text] [Related]
6. Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells.
Hatziioannou T; Cowan S; Bieniasz PD
J Virol; 2004 Jan; 78(2):1006-11. PubMed ID: 14694132
[TBL] [Abstract][Full Text] [Related]
7. Cellular entry via an actin and clathrin-dependent route is required for Lv2 restriction of HIV-2.
Harrison IP; McKnight A
Virology; 2011 Jun; 415(1):47-55. PubMed ID: 21514617
[TBL] [Abstract][Full Text] [Related]
8. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction.
Marchant D; Neil SJ; Aubin K; Schmitz C; McKnight A
J Virol; 2005 Aug; 79(15):9410-8. PubMed ID: 16014904
[TBL] [Abstract][Full Text] [Related]
9. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.
Haglund K; Forman J; Kräusslich HG; Rose JK
Virology; 2000 Mar; 268(1):112-21. PubMed ID: 10683333
[TBL] [Abstract][Full Text] [Related]
10. Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.
Kiernan RE; Ono A; Englund G; Freed EO
J Virol; 1998 May; 72(5):4116-26. PubMed ID: 9557701
[TBL] [Abstract][Full Text] [Related]
11. Degradation of SAMHD1 by Vpx Is Independent of Uncoating.
Jáuregui P; Logue EC; Schultz ML; Fung S; Landau NR
J Virol; 2015 May; 89(10):5701-13. PubMed ID: 25762741
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.
Owens RJ; Dubay JW; Hunter E; Compans RW
Proc Natl Acad Sci U S A; 1991 May; 88(9):3987-91. PubMed ID: 2023946
[TBL] [Abstract][Full Text] [Related]
13. Budding and secretion of HIV Gag-Env virus-like particles from recombinant human adenovirus infected cells.
Luo L; Li Y; Yong Kang C
Virus Res; 2003 Mar; 92(1):75-82. PubMed ID: 12606078
[TBL] [Abstract][Full Text] [Related]
14. Complex determinants within the Moloney murine leukemia virus capsid modulate susceptibility of the virus to Fv1 and Ref1-mediated restriction.
Ulm JW; Perron M; Sodroski J; C Mulligan R
Virology; 2007 Jul; 363(2):245-55. PubMed ID: 17343889
[TBL] [Abstract][Full Text] [Related]
15. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
Kräusslich HG; Ochsenbauer C; Traenckner AM; Mergener K; Fäcke M; Gelderblom HR; Bosch V
Virology; 1993 Feb; 192(2):605-17. PubMed ID: 8421902
[TBL] [Abstract][Full Text] [Related]
16. Generation and characterization of a stable full-length ecotropic murine leukemia virus molecular clone that produces novel phenotypes to Fv1 restriction.
Bae EH; Park SH; Park SM; Park JW; Lim MS; Jung YT
J Microbiol Biotechnol; 2008 Apr; 18(4):799-804. PubMed ID: 18467880
[TBL] [Abstract][Full Text] [Related]
17. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
Ding SF; Lombardi R; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein.
Freed EO; Myers DJ
J Virol; 1992 Sep; 66(9):5472-8. PubMed ID: 1501283
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication.
Casella CR; Raffini LJ; Panganiban AT
Virology; 1997 Feb; 228(2):294-306. PubMed ID: 9123837
[TBL] [Abstract][Full Text] [Related]
20. Sequence Determinants in Gammaretroviral Env Cytoplasmic Tails Dictate Virus-Specific Pseudotyping Compatibility.
Song YE; Olinger GY; Janaka SK; Johnson MC
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
